-The Business Standard NPPA to soon notify prices in line with new pharma pricing policy Some key cancer drugs, antibiotics and medicines to treat cardiovascular diseases and tuberculosis are set to become cheaper by up to 50 per cent within the next 45 days. The National Pharmaceutical Pricing Authority (NPPA) will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according...
More »SEARCH RESULT
Cancer medication as low as Rs 1,000/month on way -Malathy Iyer
-The Times of India MUMBAI: It's widely known that a month's dose of cancer drugs can cost lakhs, but what isn't common knowledge is that Tata Memorial Hospital's doctors are working on alternatives that could cost less than Rs 1,000 a month. Dubbed the metronomic treatment protocol, it comprises daily consumption of a combination of low-dose medicines that are cheap because they have been around for decades. "There is no need to...
More »RTI brings to light drug trial on humans -Syed Intishab Ali
-The Times of India JAIPUR: A doctor conducted drug trial on heart patients but seven of them died during trial of the drug. Moreover, another doctor conducted drug trials of different companies and 10 of his Cancer patients died during the trials. An RTI filed by a government-run Indore hospital Dr Anand Rai exposed deaths leading to drug trials in entire country. Answering to the RTI, office ofdrug controller general, ministry of...
More »In the ‘pharmacy of the world’ -PT Jyothi Datta
-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...
More »The Cost of Drugs: Beyond the Supreme Court Order -Sanjay Nagral
-Economic and Political Weekly While the Supreme Court decision in the recent Novartis case has cleared the way for production of generic drugs in India, doctors have to prescribe cheaper alternatives to costly brands if patients with limited means are to benefit. What is being hailed as a victory in the struggle for affordable medicines in the country will actually be one only when there is a pro-patient slant to the...
More »